Serum chemerin as a predictor of left ventricle hypertrophy in patients with coronary artery disease
2019; Medknow; Volume: 16; Issue: 1 Linguagem: Inglês
10.4103/njc.njc_20_18
ISSN2347-3576
AutoresNohaHasssanin Hanboly, Yasser Sharaf, Mervat Al-Anany, Essam Saeed,
Tópico(s)Biomarkers in Disease Mechanisms
ResumoBackground: Left ventricular hypertrophy (LVH) is an important predictor of cardiovascular risk and its detection contributes to risk stratification. Chemerin is a secreted protein with a complex but well-established role in immune function. It regulates adipocyte development and metabolic function as well as glucose metabolism in liver and skeletal muscle tissues.Purpose of the Study: The aim of the current study was to investigate the correlation between the serum chemerin level and occurrence of LVH in patients with coronary artery disease (CAD).Patients and Methods: The study included 100 patients with CAD. Patients were classified according to their body mass index (BMI) into two groups, 50 patients (Group A) with BMI (≥30 kg/m2) and 50 patients (Group B) with BMI ≤25 kg/m2. Transthoracic echocardiography was done for all patients after a thorough clinical assessment. Left ventricular study was done according to the guidelines endorsed by the American society of echocardiography.Results: Serum chemerin level was positively correlated with BMI, waist circumference, and left ventricle mass index (P < 0.005 for all).Conclusion: Serum chemerin levels were higher in obese patients with CAD. Levels were associated with LVH and increased high-sensitivity C-reactive protein as a marker of inflammation.
Referência(s)